Age <1m or > 24 months of age
No secure diagnosis of epilepsy
< 4 seizures/week on average in baseline period
Trial of < 2 AEDs
Continues on corticosteroids in previous 3 months prior to randomisation
Metabolic disease contraindicating use of the ketogenic diet e.g. pyruvate carboxylase deficiency, MCAD from previous medical investigation and screening at baseline.
Progressive neurological disease
Severe gastroesophageal reflux
Previous treatment with the ketogenic diet
Concurrent participation in another clinical trial of an investigational medicinal product.
Patients who are prescribed AEDs not listed in the trial IMPs

NCT02205931_exc_T1
Person
Age
NCT02205931_exc_T2
Value
<1m or > 24 months of age
NCT02205931_exc_T3
Negation
No
NCT02205931_exc_T4
Condition
epilepsy
NCT02205931_exc_T5
Condition
seizures
NCT02205931_exc_T6
Multiplier
4 s eek o
NCT02205931_exc_T7
Drug
AEDs
NCT02205931_exc_T8
Multiplier
< 2
NCT02205931_exc_T9
Drug
corticosteroids
NCT02205931_exc_T10
Temporal
previous 3 months prior to randomisation
NCT02205931_exc_T11
Reference_point
randomisation
NCT02205931_exc_T12
Condition
Metabolic disease
NCT02205931_exc_T13
Condition
contraindicating
NCT02205931_exc_T14
Procedure
ketogenic diet
NCT02205931_exc_T15
Condition
pyruvate carboxylase deficiency,
NCT02205931_exc_T16
Condition
MCAD
NCT02205931_exc_T17
Scope
pyruvate carboxylase deficiency, MCAD
NCT02205931_exc_T18
Condition
neurological disease
NCT02205931_exc_T19
Qualifier
Progressive
NCT02205931_exc_T20
Condition
gastroesophageal reflux
NCT02205931_exc_T21
Qualifier
Severe
NCT02205931_exc_T22
Procedure
ketogenic diet
NCT02205931_exc_T23
Qualifier
Previous